A Study of Docetaxel in Combination With Capecitabine in Stomach and Esophagus Cancers
This study has been terminated.
(Roche has withdrawn support as no longer aligned with their medical strategy for Xeloda)
Sponsor:
University of Pittsburgh
Collaborators:
Aventis Pharmaceuticals
Roche Pharma AG
Information provided by:
University of Pittsburgh
ClinicalTrials.gov Identifier:
NCT00177255
First received: September 12, 2005
Last updated: April 28, 2011
Last verified: April 2011
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study has been terminated. |
|---|---|
| Study Completion Date: | December 2008 |
| Primary Completion Date: | December 2008 (Final data collection date for primary outcome measure) |